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ABSTRACT
The phase III, randomized, open-label Check-
Mate 025 study showed an overall survival
benefit in patients with advanced renal cell
carcinoma treated with nivolumab versus ever-
olimus. Here, we review the health-related
quality of life (HRQoL) results of this trial, in
which nivolumab was associated with signifi-
cant improvements in HRQoL, with more
patients having a clinically meaningful HRQoL
improvement and a shorter time to onset of
improvement compared with everolimus. Fur-
ther exploratory analysis suggests a positive
correlation between baseline HRQoL scores and
overall survival. These results support the use of
HRQoL as a valuable measure of patient per-
spective that could translate into better clinical
outcomes and should be taken into account
during treatment selection.
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In cancer, health-related quality of life (HRQoL)
is a composite indicator of tumor symptoms
and adverse events (AEs) from treatment that
may reveal differences in patients’ perceptions
of tolerability that are not captured from stan-
dard AE reporting measures. In metastatic renal
cell carcinoma, for example, studies of tyrosine
kinase inhibitors (TKIs) in the first-line setting
have demonstrated the important effect that
differing AE profiles can have on patient pref-
erences for treatments. In the COMPARZ study,
patient perceptions of greater fatigue, mouth/
throat soreness, and foot soreness with suni-
tinib versus pazopanib were consistent with
physician-assessed AEs and associated with
lower treatment satisfaction [1]. However, in
the PISCES study, significantly more patients
preferred pazopanib over sunitinib (70% vs.
22%; P\0.001) despite an equal or worse inci-
dence of AEs. Better HRQoL was commonly
cited by patients as a reason for preferring
pazopanib. Patient preference was consistent
with physician preference (61% vs. 22%) [2].
These results suggest that perceptions of HRQoL
are multifaceted and subjective, and cannot be
captured by incidence and severity of individual
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AEs—possibly because of individual variations
in frequency and severity, and because of dif-
ferences in patients’ perceptions of the rele-
vance of certain AEs. While physicians tend to
focus on more serious AEs, these studies illus-
trate the importance of low-grade AEs and their
perception for patients’ HRQoL.
A comparison of the effects on HRQoL of an
immune checkpoint programmed death-1
(PD-1) inhibitor (nivolumab) with the mecha-
nistic target of rapamycin (mTOR) inhibitor
everolimus in patients with advanced renal cell
carcinoma has recently been published [3].
CheckMate 025 was a robustly designed study
comparing nivolumab and everolimus in a large
patient population (n = 821) with renal cell
carcinoma who had received prior antiangio-
genic therapy [4]. All procedures followed in the
study were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from all patients before they were
included in the study. The primary endpoint of
the study was overall survival; secondary end-
points included the objective response rate,
progression-free survival, and safety. The mini-
mum follow-up period was 14 months. Median
overall survival was 25.0 months [95% confi-
dence interval (CI) 21.8–not reached] in the
nivolumab group and 19.6 months (95% CI
17.6–23.1) in the everolimus group [hazard ratio
(HR) 0.73; 98.5% CI 0.57–0.93; P = 0.002]. The
objective response rate was higher with nivo-
lumab than with everolimus (25% vs. 5%; odds
ratio 5.98; 95% CI 3.68–9.72; P\0.001). Med-
ian progression-free survival was 4.6 months
(95% CI 3.7–5.4) in the nivolumab group and
4.4 months (95% CI 3.7–5.5) in the everolimus
group (HR, 0.88; 95% CI 0.75–1.03; P = 0.11).
The incidence of treatment-related AEs was
lower in the nivolumab group (79%) compared
with the everolimus group (88%) [4]. HRQoL
was assessed using the nine-item Functional
Assessment of Cancer Therapy–Kidney Symp-
tom Index–Disease-Related Symptoms
(FKSI-DRS) questionnaire that measures symp-
toms predominantly related to kidney cancer
(energy, pain, weight loss, bone pain, fatigue,
dyspnea, cough, fevers, and hematuria) [3]. The
study had high HRQoL questionnaire comple-
tion rates (86–89%). Nivolumab was associated
with significant improvement in HRQoL that
began in week 20 and lasted the duration of the
study. Compared with everolimus, the change
from baseline to week 84 was statistically sig-
nificant and observed in all items of the
FKSI-DRS except bone pain [4]. More patients
had a clinically meaningful HRQoL improve-
ment with nivolumab compared with ever-
olimus (55% vs. 37%, respectively), and the
time to onset of improvement was shorter with
nivolumab [3]. Although the open-label nature
of the study could have induced a biased
response, this seems unlikely to have been a
major factor, given that the effects were
long-lasting. In addition, the relationship
between the clinical response and quality of life
(QoL) components is complex, in part because
the latter, being a patient-reported outcome
(PRO), reflects subjective differences in the
individual reports of changes in HRQoL.
The improvement observed with nivolumab
compared with everolimus in CheckMate 025 is
notable, given the efficacy and safety profile of
everolimus in the treatment of renal cell carci-
noma [4]. Furthermore, the QoL improvement
with nivolumab was linked to improvements in
clinical outcomes, which suggests that the
effect is associated with treatment efficacy
rather than the absence of TKI-related AEs. An
exploratory analysis showed a positive correla-
tion between baseline HRQoL scores and overall
survival [3], and tumor responses with nivolu-
mab tended to occur before HRQoL improve-
ments: the median time to tumor response was
3.5 months (range 1.4–24.8), while the time to
HRQoL response was 4.7 months (95% CI
3.7–7.5) [3, 4]. However, the magnitude of the
effect suggests that patients treated with nivo-
lumab experience greater treatment benefit
than might be expected on the basis of the
objective tumor response rate.
The study also found that baseline QoL has
prognostic value. Conventionally, a patient’s
prognosis is determined through a review of
clinical parameters, as exemplified by the
Memorial Sloan Kettering Cancer Center prog-
nostic criteria. These results suggest that a
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patient’s reported QoL provides additional
information that may allow a more accurate
estimate of prognosis. It is noteworthy, how-
ever, that nivolumab was associated with better
clinical outcomes than everolimus (except for
progression-free survival), regardless of baseline
HRQoL [3].
The HRQoL instruments used in this study
are the current mainstay for the assessment of
QoL, although the therapeutic landscape has
changed considerably since they were devel-
oped. The PRO version of the Common Termi-
nology Criteria for Adverse Events
(PRO-CTCAE) is a recently developed instru-
ment that employs a flexible, fit-for-purpose
approach to assess the frequency of, severity of,
and interference from symptomatic treat-
ment-associated toxicities [5]. While the appli-
cability and validity of newer tools such as the
PRO-CTCAE are yet to be established for treat-
ment with TKIs or immune checkpoint block-
ade, they may be used in future studies.
Nevertheless, existing tools still capture the
benefit of novel agents, as demonstrated by the
CheckMate 025 QoL results.
CONCLUSIONS
Tolerability is an increasingly important aspect
of renal cell carcinoma management, as
patients are living longer due to efficacy
advantages of modern treatments. HRQoL data
provide an overall assessment of the
patient-centered impact of treatment-related
AEs, and the rapid and sustained HRQoL bene-
fits of nivolumab reflect reduced treatment-re-
lated toxicity. This, and the higher number of
patients with a clinically meaningful HRQoL
response with nivolumab compared with ever-
olimus, strengthens and supports observations
of improved clinical outcomes.
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